Immatics Biotechnologies Gmbh Stock Total Asset
| IMTXW Stock | USD 0.41 0.01 2.38% |
immatics biotechnologies GmbH fundamentals help investors to digest information that contributes to Immatics Biotechnologies' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics Biotechnologies stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 510 M | 325.9 M |
Immatics | Total Asset |
immatics biotechnologies GmbH Company Total Asset Analysis
Immatics Biotechnologies' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Immatics Biotechnologies Total Asset | 509.96 M |
Most of Immatics Biotechnologies' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, immatics biotechnologies GmbH is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immatics Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics Biotechnologies is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Total Asset. Since Immatics Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Immatics Total Asset Historical Pattern
Today, most investors in Immatics Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immatics Biotechnologies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immatics Biotechnologies total asset as a starting point in their analysis.
Immatics Biotechnologies Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Immatics Total Assets
Total Assets |
|
Based on the latest financial disclosure, immatics biotechnologies GmbH has a Total Asset of 509.96 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is notably lower than that of the firm.
Immatics Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics Biotechnologies' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics Biotechnologies could also be used in its relative valuation, which is a method of valuing Immatics Biotechnologies by comparing valuation metrics of similar companies.Immatics Biotechnologies is currently under evaluation in total asset category among its peers.
Immatics Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immatics Biotechnologies from analyzing Immatics Biotechnologies' financial statements. These drivers represent accounts that assess Immatics Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immatics Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 583.4M | 423.8M | 743.6M | 546.8M | 767.3M | 480.3M | |
| Enterprise Value | 483.3M | 222.4M | 620.4M | 412.8M | 564.3M | 373.5M |
Immatics Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Number Of Shares Shorted | 736 | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) | ||||
| Net Income | (96.99 M) | ||||
| Total Debt | 15.4 M | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Number Of Employees | 542 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 673 M | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
| Working Capital | 292.82 M | ||||
| Net Asset | 509.96 M |
About Immatics Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze immatics biotechnologies GmbH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of immatics biotechnologies GmbH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.